Entera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28

Entera Bio (ENTX) reported a wider Q2 net loss, driven by a surge in financial expenses and more than doubling research & development costs. The company also outlined plans to initiate Phase 3 clinical activity (per the excerpt), but near-term profitability pressure remains the key takeaway for investors.

Analysis

Entera Bio (ENTX) reported a wider Q2 net loss, driven by a surge in financial expenses and more than doubling research & development costs. The company also outlined plans to initiate Phase 3 clinical activity (per the excerpt), but near-term profitability pressure remains the key takeaway for investors.